https://www.live-feeds.com/feed/vaxcyte-s-stock-jumps-as-pneumococcal-vaccine-holds-its-own-against-pfizer-s-merck-s-shotsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/vaxcyte-s-stock-jumps-as-pneumococcal-vaccine-holds-its-own-against-pfizer-s-merck-s-shotshttps://www.live-feeds.com/feed/vaxcyte-s-stock-jumps-as-pneumococcal-vaccine-holds-its-own-against-pfizer-s-merck-s-shots#u110438Thu, 08 Oct 2026 10:45:47 +0000Vaxcyte shares surged following positive late-stage trial results for its lead pneumococcal vaccine candidate, VAX-31. The vaccine met every primary goal in its adult Phase 3 trial named OPUS-1, demonstrating non-inferiority against established standard-of-care jabs from major pharmaceutical competitors. VAX-31 cleared a stringent bar against Pfizer's Prevnar 20 on all shared strains, while also performing strongly against Merck's Capvaxive. The successful trial data exceeded investor expectations, driving a sharp increase in the company stock value and positioning the biotech firm t